Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2006

Open Access 01-12-2006 | Research

Allergens induce enhanced bronchoconstriction and leukotriene production in C5 deficient mice

Authors: Laura McKinley, Jiyoun Kim, Gerald L Bolgos, Javed Siddiqui, Daniel G Remick

Published in: Respiratory Research | Issue 1/2006

Login to get access

Abstract

Background

Previous genetic analysis has shown that a deletion in the complement component 5 gene-coding region renders mice more susceptible to allergen-induced airway hyperresponsiveness (AHR) due to reduced IL-12 production. We investigated the role of complement in a murine model of asthma-like pulmonary inflammation.

Methods

In order to evaluate the role of complement B10 mice either sufficient or deficient in C5 were studied. Both groups of mice immunized and challenged with a house dust extract (HDE) containing high levels of cockroach allergens. Airways hyper-reactivity was determined with whole-body plesthysmography. Bronchoalveolar lavage (BAL) was performed to determine pulmonary cellular recruitment and measure inflammatory mediators. Lung homogenates were assayed for mediators and plasma levels of IgE determined. Pulmonary histology was also evaluated.

Results

C5-deficient mice showed enhanced AHR to methylcholine challenge, 474% and 91% increase above baseline Penh in C5-deficient and C5-sufficient mice respectively, p < 0.001. IL-12 levels in the lung homogenate (LH) were only slightly reduced and BAL IL-12 was comparable in C5-sufficient and C5-deficient mice. However, C5-deficient mice had significantly higher cysteinyl-leukotriene levels in the BAL fluid, 1913 +/- 246 pg/ml in C5d and 756 +/- 232 pg/ml in C5-sufficient, p = 0.003.

Conclusion

These data demonstrate that C5-deficient mice show enhanced AHR due to increased production of cysteinyl-leukotrienes.
Literature
1.
Herrick CA, Bottomly K: To respond or not to respond: T cells in allergic asthma. Nat Rev Immunol 2003,3(5):405–412.PubMedCrossRef
2.
Krug N, Tschernig T, Erpenbeck VJ, Hohlfeld JM, Kohl J: Complement factors C3a and C5a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthma. Am J Respir Crit Care Med 2001,164(10 Pt 1):1841–1843.PubMedCrossRef
3.
Bautsch W, Hoymann HG, Zhang Q, Meier-Wiedenbach I, Raschke U, Ames RS, Sohns B, Flemme N, Meyer zu Vilsendorf A, Grove M, Klos A, Kohl J: Cutting edge: guinea pigs with a natural C3a-receptor defect exhibit decreased bronchoconstriction in allergic airway disease: evidence for an involvement of the C3a anaphylatoxin in the pathogenesis of asthma. J Immunol 2000,165(10):5401–5405.PubMedCrossRef
4.
Humbles AA, Lu B, Nilsson CA, Lilly C, Israel E, Fujiwara Y, Gerard NP, Gerard C: A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 2000,406(6799):998–1001.PubMedCrossRef
5.
Drouin SM, Corry DB, Kildsgaard J, Wetsel RA: Cutting edge: the absence of C3 demonstrates a role for complement in Th2 effector functions in a murine model of pulmonary allergy. J Immunol 2001,167(8):4141–4145.PubMedCrossRef
6.
Drouin SM, Corry DB, Hollman TJ, Kildsgaard J, Wetsel RA: Absence of the complement anaphylatoxin C3a receptor suppresses Th2 effector functions in a murine model of pulmonary allergy. J Immunol 2002,169(10):5926–5933.PubMedCrossRef
7.
Karp CL, Grupe A, Schadt E, Ewart SL, Keane-Moore M, Cuomo PJ, Kohl J, Wahl L, Kuperman D, Germer S, Aud D, Peltz G, Wills-Karp M: Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma. Nat Immunol 2000,1(3):221–226.PubMedCrossRef
8.
Rosenstreich DL, Eggleston P, Kattan M, Baker D, Slavin RG, Gergen P, Mitchell H, McNiff-Mortimer K, Lynn H, Ownby D, Malveaux F: The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma [see comments]. New England Journal of Medicine 1997,336(19):1356–1363.PubMedCrossRef
9.
Nilsson UR, Muller-Eberhard HJ: Deficiency of the fifth component of complement in mice with an inherited complement defect. J Exp Med 1967,125(1):1–16.PubMedPubMedCentralCrossRef
10.
Haviland DL, Haviland JC, Fleischer DT, Wetsel RA: Structure of the murine fifth complement component (C5) gene. A large, highly interrupted gene with a variant donor splice site and organizational homology with the third and fourth complement component genes. J Biol Chem 1991,266(18):11818–11825.PubMed
11.
Kim J, Merry AC, Nemzek JA, Bolgos GL, Siddiqui J, Remick DG: Eotaxin Represents the Principal Eosinophil Chemoattractant in a Novel Murine Asthma Model Induced by House Dust Containing Cockroach Allergens. J Immunol 2001,167(5):2808–2815.PubMedCrossRef
12.
Hamelmann E, Schwarze J, Takeda K, Oshiba A, Larsen GL, Irvin CG, Gelfand EW: Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography [see comments]. Am J Respir Crit Care Med 1997,156(3 Pt 1):766–775.PubMedCrossRef
13.
Lundblad LK, Irvin CG, Adler A, Bates JH: A reevaluation of the validity of unrestrained plethysmography in mice. J Appl Physiol 2002,93(4):1198–1207.PubMedCrossRef
14.
Nemzek JA, Siddiqui J, Remick DG: Development and optimization of cytokine ELISAs using commercial antibody pairs. J Immunol Methods 2001,255(1–2):149–157.PubMedCrossRef
15.
McKinley L, Kim J, Bolgos GL, Siddiqui J, Remick DG: Reproducibility of a novel model of murine asthma-like pulmonary inflammation. Clin Exp Immunol 2004,136(2):224–231.PubMedPubMedCentralCrossRef
16.
Dahlen SE, Hedqvist P, Hammarstrom S, Samuelsson B: Leukotrienes are potent constrictors of human bronchi. Nature 1980,288(5790):484–486.PubMedCrossRef
17.
Coles SJ, Neill KH, Reid LM, Austen KF, Nii Y, Corey EJ, Lewis RA: Effects of leukotrienes C4 and D4 on glycoprotein and lysozyme secretion by human bronchial mucosa. Prostaglandins 1983,25(2):155–170.PubMedCrossRef
18.
Ochensberger B, Tassera L, Bifrare D, Rihs S, Dahinden CA: Regulation of cytokine expression and leukotriene formation in human basophils by growth factors, chemokines and chemotactic agonists. Eur J Immunol 1999,29(1):11–22.PubMedCrossRef
19.
Abrahamsen O, Haas H, Schreiber J, Schlaak M: Differential mediator release from basophils of allergic and non-allergic asthmatic patients after stimulation with anti-IgE and C5a. Clin Exp Allergy 2001,31(3):368–378.PubMedCrossRef
20.
Hartmann K, Henz BM, Kruger-Krasagakes S, Kohl J, Burger R, Guhl S, Haase I, Lippert U, Zuberbier T: C3a and C5a stimulate chemotaxis of human mast cells. Blood 1997,89(8):2863–2870.PubMed
21.
Mousli M, Hugli TE, Landry Y, Bronner C: A mechanism of action for anaphylatoxin C3a stimulation of mast cells. J Immunol 1992,148(8):2456–2461.PubMed
22.
Hawlisch H, Wills-Karp M, Karp CL, Kohl J: The anaphylatoxins bridge innate and adaptive immune responses in allergic asthma. Mol Immunol 2004,41(2–3):123–131.PubMedCrossRef
23.
Maruo K, Akaike T, Ono T, Okamoto T, Maeda H: Generation of anaphylatoxins through proteolytic processing of C3 and C5 by house dust mite protease. J Allergy Clin Immunol 1997,100(2):253–260.PubMedCrossRef
24.
Castro FF, Schmitz-Schumann M, Rother U, Kirschfink M: Complement activation by house dust: reduced reactivity of serum complement in patients with bronchial asthma. Int Arch Allergy Appl Immunol 1991,96(4):305–310.PubMedCrossRef
25.
Sozzani S, Sallusto F, Luini W, Zhou D, Piemonti L, Allavena P, Van Damme J, Valitutti S, Lanzavecchia A, Mantovani A: Migration of dendritic cells in response to formyl peptides, C5a, and a distinct set of chemokines. J Immunol 1995,155(7):3292–3295.PubMed
26.
Daffern PJ, Pfeifer PH, Ember JA, Hugli TE: C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J Exp Med 1995,181(6):2119–2127.PubMedCrossRef
27.
DiScipio RG, Daffern PJ, Jagels MA, Broide DH, Sriramarao P: A comparison of C3a and C5a-mediated stable adhesion of rolling eosinophils in postcapillary venules and transendothelial migration in vitro and in vivo. J Immunol 1999,162(2):1127–1136.PubMed
28.
Nataf S, Davoust N, Ames RS, Barnum SR: Human T cells express the C5a receptor and are chemoattracted to C5a. J Immunol 1999,162(7):4018–4023.PubMed
29.
Ponath PD, Qin S, Ringler DJ, Clark-Lewis I, Wang J, Kassam N, Smith H, Shi X, Gonzalo JA, Newman W, Gutierrez-Ramos JC, Mackay CR: Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest 1996,97(3):604–612.PubMedPubMedCentralCrossRef
30.
Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, Luster AD: Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med 1996,2(4):449–456.PubMedCrossRef
31.
Corry DB, Folkesson HG, Warnock ML, Erle DJ, Matthay MA, Wiener-Kronish JP, Locksley RM: Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J Exp Med 1996,183(1):109–117.PubMedCrossRef
32.
Kohl J, Baelder R, Lewkowich IP, Pandey MK, Hawlisch H, Wang L, Best J, Herman NS, Sproles AA, Zwirner J, Whitsett JA, Gerard C, Sfyroera G, Lambris JD, Wills-Karp M: A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma.[see comment]. Journal of Clinical Investigation 2006,116(3):783–796.PubMedPubMedCentralCrossRef
33.
Busse WW: Leukotrienes and inflammation. Am J Respir Crit Care Med 1998,157(6 Pt 1):S210–3.CrossRef
34.
Drazen JM: Leukotrienes as mediators of airway obstruction. Am J Respir Crit Care Med 1998,158(5 Pt 3):S193–200.PubMedCrossRef
35.
Eglite S, Pluss K, Dahinden CA: Requirements for C5a receptor-mediated IL-4 and IL-13 production and leukotriene C4 generation in human basophils. J Immunol 2000,165(4):2183–2189.PubMedCrossRef
36.
Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN: Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987,237(4819):1171–1176.PubMedCrossRef
37.
Kobayashi T, Miura T, Haba T, Sato M, Serizawa I, Nagai H, Ishizaka K: An essential role of mast cells in the development of airway hyperresponsiveness in a murine asthma model. J Immunol 2000,164(7):3855–3861.PubMedCrossRef
38.
Williams CM, Galli SJ: Mast cells can amplify airway reactivity and features of chronic inflammation in an asthma model in mice. J Exp Med 2000,192(3):455–462.PubMedPubMedCentralCrossRef
39.
Koshino T, Arai Y, Miyamoto Y, Sano Y, Takaishi T, Hirai K, Ito K, Morita Y: Mast cell and basophil number in the airway correlate with the bronchial responsiveness of asthmatics. Int Arch Allergy Immunol 1995,107(1–3):378–379.PubMedCrossRef
40.
Walters DM, Breysse PN, Schofield B, Wills-Karp M: Complement factor 3 mediates particulate matter-induced airway hyperresponsiveness. Am J Respir Cell Mol Biol 2002,27(4):413–418.PubMedCrossRef
41.
Abe M, Shibata K, Akatsu H, Shimizu N, Sakata N, Katsuragi T, Okada H: Contribution of anaphylatoxin C5a to late airway responses after repeated exposure of antigen to allergic rats. J Immunol 2001,167(8):4651–4660.PubMedCrossRef
42.
Taube C, Rha YH, Takeda K, Park JW, Joetham A, Balhorn A, Dakhama A, Giclas PC, Holers VM, Gelfand EW: Inhibition of complement activation decreases airway inflammation and hyperresponsiveness. Am J Respir Crit Care Med 2003,168(11):1333–1341.PubMedCrossRef
43.
Baelder R, Fuchs B, Bautsch W, Zwirner J, Kohl J, Hoymann HG, Glaab T, Erpenbeck V, Krug N, Braun A: Pharmacological targeting of anaphylatoxin receptors during the effector phase of allergic asthma suppresses airway hyperresponsiveness and airway inflammation. J Immunol 2005,174(2):783–789.PubMedCrossRef
Metadata
Title
Allergens induce enhanced bronchoconstriction and leukotriene production in C5 deficient mice
Authors
Laura McKinley
Jiyoun Kim
Gerald L Bolgos
Javed Siddiqui
Daniel G Remick
Publication date
01-12-2006
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2006
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-7-129

Other articles of this Issue 1/2006

Respiratory Research 1/2006 Go to the issue

Research

Modulation of glutaredoxin in the lung and sputum of cigarette smokers and chronic obstructive pulmonary disease

Research

Apoptosis of viral-infected airway epithelial cells limit viral production and is altered by corticosteroid exposure

Research

Mucociliary and long-term particle clearance in airways of patients with immotile cilia

Research

Tooth loss and obstructive sleep apnoea

Research

The Directly Observed Therapy Short-Course (DOTS) strategy in Samara Oblast, Russian Federation

Research

Activation of chloride transport in CF airway epithelial cell lines and primary CF nasal epithelial cells by S-nitrosoglutathione
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits